chemieunternehmen.com

According to a press release published today by Novo Holdings, a new fund has been launched focused on new approaches to fight against antimicrobial resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/novo-holdings-announce-launch-of-repair-and-formation-of-scientific-selection-board-5641

Evotec AG and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-mars-innovation-announce-first-funded-project-under-lab150-bridge-5639

Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party alliance signed in August 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-achieve-first-milestone-in-immuno-oncology-alliance-with-sanofi-5635

Evotec AG today announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden („CRTD“) to discover novel small molecule candidates for retinal diseases.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-research-collaboration-with-crtd-to-discover-novel-therapies-for-retinal-diseases-5652

Evotec AG announced today that LAB282, the £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-academic-bridge-lab282-with-oxford-university-celebrating-one-year-of-impact-5526

Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/ncardia-and-evotec-entered-a-licencing-agreement-for-disease-modelling-using-ips-cells-5523

Evotec AG announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of EUR 2.00 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-clinical-milestone-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5520

Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, today announced that the first patient has been dosed in the phase 1 clinical programme of CT7001 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-its-oral-cdk7-inhibitor-ct7001-5517

Evotec AG today reported financial results and corporate updates for the first nine months of 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-announces-first-nine-month-2017-results-and-corporate-update-5512